Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) reported a net loss of $8.8 million for Q3 2022 compared to $2.2 million in Q3 2021, influenced by a prior year tax credit. Operating expenses decreased to $8.2 million from $14.0 million due to reduced clinical trial costs. The company is advancing its CRB-601 therapy, with IND submission planned for mid-2023, and positive pre-clinical data will be presented at SITC 2022. Cash reserves of $67 million are expected to support operations through Q2 2024.
- CRB-601 shows promising anti-tumor activity in combination with anti PD-1 therapy.
- Cash position of $67 million secures operations through Q2 2024.
- Net loss increased to $8.8 million in Q3 2022 from $2.2 million in Q3 2021.
- Amended debt agreement deferring principal payments impacts financial strategy.
- Latest pre-clinical data for CRB-601 monotherapy and in combination with anti-PD1 therapy to be presented this Thursday at SITC 2022
- IND submission for CRB-601 is on track for mid-2023
- Expanding oncology pipeline through strategic transactions remains key priority
- Cash and investments on hand of
$67 million funds operations through the second quarter of 2024
NORWOOD, Mass., Nov. 8, 2022 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an oncology company, today provided a corporate update and reported financial results for the third quarter of 2022.
Key Corporate and Program Updates:
- Anti-integrin monoclonal antibody (mAb) programs targeting the inhibition of TGFβ are progressing on schedule
- CRB-601, an anti-αvβ8 mAb, is being developed as a potential treatment for solid tumors.
- Across models explored to-date, CRB-601 demonstrates an enhancement of anti-tumor activity when combined with anti PD-1 therapy compared to either single agent alone. Latest data to be presented this Thursday at SITC 2022.
- Data supports the hypothesis that blockade of latent TGFb production by CRB-601 can lead to changes in immune cell infiltration in the tumor microenvironment, potentially enhancing the benefit of PD-1 blockade.
- IND-enabling activities for CRB-601 are ongoing and the program is on schedule for an IND submission in mid-2023.
- Recent clinical updates from investigational therapies also targeting latent TGFb reinforce the promise of this novel approach in oncology.
- CB1 inverse agonist program for obesity / metabolism
- CRB-913, a novel CB1 inverse agonist with highly differentiated PK from other members of its class, has demonstrated weight loss and improvement in multiple metabolic parameters, as monotherapy and in combination within liraglutide, semaglutide and tirzepatide in animal models of diet-induced obesity.
- New data was shared in an oral presentation at the annual meeting of the European Association for the Study of Diabetes (EASD) in September 2022. View the presentation here.
- Data is being prepared for publication.
- Corbus is actively exploring partnerships to advance CRB-913 into clinical studies.
- A detailed update on the Corbus pipeline can be found in the most recent Corporate Presentation available on the Company's website here.
"We continue to progress CRB-601 toward the clinic on schedule and on budget. Our latest pre-clinical data, to be presented this Thursday at SITC 2022, further reinforces our belief that this could be a highly impactful drug in oncology therapy, and we look forward to the latest clinical updates from this field," commented Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "We continue to be actively engaged in business development activities with the goal of expanding our pipeline while also bringing in non-dilutive funding by monetizing our portfolio of endocannabinoid assets through new partnerships."
Financial Results for Third Quarter Ended September 30, 2022:
The Company reported a net loss of approximately
Operating expenses for Q3 2022 decreased by
In October of 2022, the Company amended its debt agreement with K2 HealthVentures LLC to defer commencement of principal payments by one year until September 2023 which improved the Company's liquidity and cash runway. As of September 30, 2022, the Company has
About Corbus
Corbus is an oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' current pipeline includes anti-integrin monoclonal antibodies that block activation of TGFβ and small molecules that activate or inhibit the endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors, including the potential impact of the recent COVID-19 pandemic and the potential impact of sustained social distancing efforts, on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACTS:
Sean Moran
Chief Financial Officer
smoran@corbuspharma.com
Bruce Mackle
Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Balance Sheets | ||||||||
September 30, 2022 | December 31, 2021 | |||||||
(Unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 12,443,645 | $ | 25,006,632 | ||||
Investments | 53,785,559 | 72,640,520 | ||||||
Restricted cash | 192,475 | 192,475 | ||||||
Prepaid expenses and other current assets | 926,161 | 2,365,010 | ||||||
Total current assets | 67,347,840 | 100,204,637 | ||||||
Restricted cash | 477,425 | 477,425 | ||||||
Property and equipment, net | 1,798,212 | 2,392,696 | ||||||
Operating lease right of use assets | 4,074,074 | 4,609,110 | ||||||
Other assets | 133,055 | 46,385 | ||||||
Total assets | $ | 73,830,606 | $ | 107,730,253 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Notes payable | $ | — | $ | 767,938 | ||||
Accounts payable | 1,374,220 | 1,782,277 | ||||||
Accrued expenses | 4,833,839 | 10,093,312 | ||||||
Derivative liability | 133,710 | 133,710 | ||||||
Operating lease liabilities, current | 1,243,802 | 1,136,948 | ||||||
Current portion of long-term debt | 9,883,638 | 3,093,344 | ||||||
Total current liabilities | 17,469,209 | 17,007,529 | ||||||
Long-term debt, net of debt discount | 9,385,847 | 15,636,275 | ||||||
Other long-term liabilities | 22,205 | 22,205 | ||||||
Operating lease liabilities, noncurrent | 5,007,236 | 5,956,217 | ||||||
Total liabilities | 31,884,497 | 38,622,226 | ||||||
Stockholders' equity | ||||||||
Preferred stock, | — | — | ||||||
Common stock, | 12,528 | 12,523 | ||||||
Additional paid-in capital | 423,342,069 | 418,891,713 | ||||||
Accumulated deficit | (381,201,614) | (349,733,764) | ||||||
Accumulated other comprehensive loss | (206,874) | (62,445) | ||||||
Total stockholders' equity | 41,946,109 | 69,108,027 | ||||||
Total liabilities and stockholders' equity | $ | 73,830,606 | $ | 107,730,253 | ||||
Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) | ||||||||||||||||
For the Three Months | For the Nine Months | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenue from awards | $ | — | $ | 97,323 | $ | — | $ | 881,705 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 4,108,190 | 8,695,641 | 9,894,068 | 30,681,684 | ||||||||||||
General and administrative | 4,073,266 | 5,277,090 | 14,144,557 | 16,190,684 | ||||||||||||
Litigation Settlement | — | — | 5,000,000 | — | ||||||||||||
Total operating expenses | 8,181,456 | 13,972,731 | 29,038,625 | 46,872,368 | ||||||||||||
Operating loss | (8,181,456) | (13,875,408) | (29,038,625) | (45,990,663) | ||||||||||||
Other income (expense), net: | ||||||||||||||||
Other income (expense), net | 77,712 | 12,033,031 | (324,322) | 11,790,328 | ||||||||||||
Interest income (expense), net | (541,889) | (391,867) | (1,491,137) | (1,439,587) | ||||||||||||
Change in fair value of derivative liability | — | 472,143 | — | 670,143 | ||||||||||||
Foreign currency exchange gain (loss), net | (136,087) | (414,048) | (613,766) | (409,914) | ||||||||||||
Other income (expense), net | (600,264) | 11,699,259 | (2,429,225) | 10,610,970 | ||||||||||||
Net loss | $ | (8,781,720) | $ | (2,176,149) | $ | (31,467,850) | $ | (35,379,693) | ||||||||
Net loss per share, basic and diluted | $ | (0.07) | $ | (0.02) | $ | (0.25) | $ | (0.29) | ||||||||
Weighted average number of common shares outstanding, basic and diluted | 125,268,381 | 125,209,985 | 125,255,927 | 122,234,847 | ||||||||||||
Comprehensive loss: | ||||||||||||||||
Net loss | $ | (8,781,720) | $ | (2,176,149) | $ | (31,467,850) | $ | (35,379,693) | ||||||||
Other comprehensive income (loss): | ||||||||||||||||
Change in unrealized gain (loss) on marketable debt securities | (87,554) | (3,513) | (144,429) | (8,967) | ||||||||||||
Total other comprehensive income (loss) | (87,554) | (3,513) | (144,429) | (8,967) | ||||||||||||
Total comprehensive loss | $ | (8,869,274) | $ | (2,179,662) | $ | (31,612,279) | $ | (35,388,660) | ||||||||
View original content to download multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-reports-third-quarter-2022-financial-results-and-provides-corporate-update-301671545.html
SOURCE Corbus Pharmaceuticals
FAQ
What are the recent financial results for Corbus Pharmaceuticals (CRBP)?
When is the IND submission for CRB-601 planned?
What are the key updates from Corbus Pharmaceuticals on CRB-601?
How much cash does Corbus Pharmaceuticals have on hand?
